Prelude Capital Management’s Starling Oncology Institute, Inc. Common Stock STLN Stock Holding History

Prelude Capital Management’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-11,880	Closed	-$41.5K	–	1552
2025 Q3	$41.5K	Buy	+11,880	New	+$40.7K	﹤0.01%	1110
2024 Q1	–	Sell	-19,629	Closed	-$40K	–	1524
2023 Q4	$40K	Sell	19,629 -30,240	-61%	-$52.4K	﹤0.01%	1082
2023 Q3	$69.8K	Buy	49,869 +8,652	+21%	+$8.96K	﹤0.01%	1020
2023 Q2	$22.7K	Buy	+41,217	New	+$21.8K	﹤0.01%	1009

Other funds holding STLN

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

CenterBook Partners Greenwich, Connecticut $1.86B AUM 24.52% 1-Year Est. Return

KWM

Kanen Wealth Management Coconut Creek, Florida $278M AUM 38.85% 1-Year Est. Return

Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $117M AUM 26.5% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $690M AUM 57.88% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Prelude Capital Management's STLN Position: Q4 2025 in Review

Prelude Capital Management sold out of Starling Oncology Institute, Inc. Common Stock (STLN) in Q4 2025, closing a stake of 11,880 shares — an estimated $41.5K sold.

Prelude Capital Management first reported a position in STLN in Q2 2023 and held it in 4 quarters. The position peaked at $69.8K in Q3 2023. 117 funds tracked by Wall St. Rank hold STLN as of Q4 2025.

Prelude Capital Management reported no remaining Starling Oncology Institute, Inc. Common Stock position as of Q4 2025 after selling out during the quarter.
Prelude Capital Management sold 11,880 Starling Oncology Institute, Inc. Common Stock shares in Q4 2025, an estimated $41.5K.
Prelude Capital Management first reported a position in Starling Oncology Institute, Inc. Common Stock in Q2 2023 and held it in 4 quarters.
Prelude Capital Management's Starling Oncology Institute, Inc. Common Stock position peaked at $69.8K in Q3 2023.
117 funds tracked by Wall St. Rank held Starling Oncology Institute, Inc. Common Stock as of Q4 2025.

Based on Prelude Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.